论文部分内容阅读
目的:研究阿司匹林对不稳定型心绞痛(UAP)治疗效果及血清M-CSF、CK-MB、sICAM-1水平变化分析。方法:选择2014年2月至2016年4月在我院进行治疗的UAP患者60名,按照不同的治疗方法分为观察组和对照组。对照组使用常规方法治疗,观察组在对照组基础上联合阿司匹林口服药物治疗。采用酶联免疫吸附法测定血清M-CSF、CK-MB、sICAM-1水平变化,对M-CSF、sICAM-1水平采用TMI危险积分进行判定并观察两组患者治疗后的临床疗效。结果:治疗后,观察组不良反应发生率为13.33%,而对照组不良反应发生率为46.67%差异显著(P<0.05);治疗后,观察组的外周血M-CSF、sICAM-1、CK-MB水平,明显低于对照组外周血水平,差异显著(P<0.05),治疗后观察组的TMI危险积分随外周血M-CSF、sICAM-1水平升高,且对比对照组水平显著差异(P<0.05)。结论:阿司匹林能够有效抑制UAP患者的冠状动脉粥样硬化的风险,且能有效改善外周血清M-CSF、CK-MB、sICAM-1水平,M-CSF、CK-MB、sICAM-1三种指标是评估UAP患者的重要参考指标。
Objective: To study the effect of aspirin on the treatment of unstable angina pectoris (UAP) and the changes of serum M-CSF, CK-MB and sICAM-1. Methods: Sixty UAP patients who were treated in our hospital from February 2014 to April 2016 were divided into observation group and control group according to different treatment methods. The control group was treated by conventional method. The observation group was treated with oral aspirin based on the control group. Serum levels of M-CSF, CK-MB and sICAM-1 were measured by enzyme-linked immunosorbent assay. The levels of M-CSF and sICAM-1 in serum were determined by TMI risk score and the clinical effects were observed after treatment. Results: After treatment, the incidence of adverse reactions in the observation group was 13.33%, while the incidence of adverse reactions in the control group was 46.67% (P <0.05). After treatment, the levels of M-CSF, sICAM-1 and CK -MB levels were significantly lower than that of the control group (P <0.05). After treatment, the levels of TMI in the observation group increased with the levels of M-CSF and sICAM-1 in the peripheral blood and the levels in the control group were significantly different (P <0.05). Conclusion: Aspirin can effectively reduce the risk of coronary atherosclerosis in patients with UAP and can effectively improve the levels of M-CSF, CK-MB, sICAM-1, M-CSF, CK-MB and sICAM-1 in peripheral blood Is an important reference for evaluating patients with UAP.